Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_47_библиотеки_им_акад_М_И_Перельмана
.pdf
476
47. Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, etal. Effect of liver cirrhosis
on the systemic availability of naltrexone in humans. J Hepatol. 1997;27:505–11.
48. Lloyd-Thomas HG, Sherlock S.Testosterone therapy for the pruritus of obstructive jaundice.
Br Med J. 1952 Dec 13;2(4797):1289–91.
49. NARCAN® Nasal Spray [prescribing information]. Plymouth Meeting PAP, Inc.; 2020. 2020
[cited 2020 December 8th, 2020]. Available from:
http://www.narcannasalspray.
50. Kamimura K, Yokoo T, Kamimura H, Sakamaki A, Abe S, Tsuchiya A, et al. Long-term
efcacy and safety of nalfurane hydrochloride on pruritus in chronic liver disease patients:
patient-reported outcome based analyses. PLoS One. 2017;12(6):e0178991.
51. Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, etal. Activation of
kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administra-
tion of morphine in monkeys. J Pharmacol Exp Ther. 2003 Apr;305(1):173–9.
52. Ko MC, Song MS, Edwards T, Lee H, Naughton NN. The role of central mu opioid
receptors in opioid-induced itch in primates. J Pharmacol Exp Ther. 2004 Jul;310(1):
169–76.
53. Reisine T.Pasternak. Opioid analgesics and antagonists. In: Molinoff PB, Ruddon RW, edi-
tors. The Pharmacologica basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996.
p.521–55.
54. Yosipovitch G, Stander S.Meeting report of the 3rd international workshop for the study of
itch. J Invest Dermatol. 2006 Sep;126(9):1928–30.
55. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad
Dermatol. 2006 Mar;54(3):527–31.
56. Stehling LC, Zauder HL.Double-blind comparison of butorphanol tartrate and meperidine
hydrochloride in balanced anaesthesia. J Int Med Res. 1978;6(5):384–7.
57. Fisher MA, Glass S.Butorphanol (Stadol): a study in problems of current drug information
and control. Neurology. 1997 May;48(5):1156–60.
58. Zylicz Z, Krajnik M.Codeine for pruritus in primary billiary cirrhosis. Lancet. 1999 Mar
6;353(9155):813.
59. Zylicz Z, Krajnik M. Codeine for pruritus in primary billiary cirrhosis [letter]. Lancet.
1999;353(9155):813.
60. Richardson BP. Serotonin and nociception. Annals of the New York Academy of Sci.
1990;600:511–20.
61. Kjellberg F, Tramer MR.Pharmacological control of opioid-induced pruritus: a quantitative
systematic review of randomized trials. Eur J Anaesthesiol. 2001;18(6):346–57.
62. Raderer M, Muller C, Scheithauer W.Ondansetron for pruritus due to cholestasis. N Engl J
Med. 1994;21:1540.
63. Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet.
1993;341:1277.
64. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, etal. Treatment of pruritus
in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondanse-
tron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol
Hepatol. 1998;10:865–70.
65. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of
drugs: 5- hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondanse-
tron. Pain. 1995;61(1):33–7.
66. O’Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R.A con-
trolled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther. 2005 Apr
15;21(8):1041–5.
67. Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in chronic liver disease: a
controlled study. Hepato-Gastroenterology. 2007 Jun;54(76):1196–9.
68. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and
management. Br J Haematol. 2001;115:619–21.
69. Zylicz Z, Krajnik M, Sorge AA, Costantini M.Paroxetine in the treatment of severe non-
dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manag. 2003
Dec;26(6):1105–12.
N. V. Bergasa
https://t.me/medicina_free
477
70. Zylicz Z, Smits C, Krajnik M.Paroxetine for pruritus in advanced cancer. J Pain Symptom
Manag. 1998 Aug;16(2):121–4.
71. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand
Suppl. 1997;391:31–7.
72. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain
Symptom Manag. 2003 Mar;25(3):288–91.
73. Hundley JL, G.Y. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus:
a pilot study. J Am Acad Dermatol. 2004;50:889–91.
74. Browning J, Combes B, Mayo MJ. Long-term efcacy of sertraline as a treatment
for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol.
2003;98(12):2736–41.
75. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ.Sertraline as a rst-line
treatment for cholestatic pruritus. Hepatology. 2007 Mar;45(3):666–74.
76. Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M.Pilot study of
bright-light therapy reected toward the eyes for the pruritus of chronic liver disease. Am J
Gastroenterol. 2001;96(5):1563–70.
77. De Vries E, Bolier R, van Buuren H, Beueres U.Fibrates for itch (FITCH) in Fibrosing
Cholangiopathies: a double-blind, randomized, placebo-controlled trial (n press).
Gastroenterology. 2020; Epub October 05, 2020
78. Reig A, Sesé P, Parés A.Effects of Bezabrate on outcome and pruritus in primary bili-
ary cholangitis with suboptimal Ursodeoxycholic acid response. Am J Gastroenterol.
2018;113(1):49–55.
79. Turner IB, Rawlins MD, Wood P, James OF.Flumecinol for the treatment of pruritus associ-
ated with primary biliary cirrhosis. Aliment Pharmacol Ther. 1994;8(3):337–42.
80. Berg CL, Gollan JL. Primary biliary cirrhosis: new therapeutic directions. Scand J
Gastroenterol Suppl. 1992;192:43–9.
81. Watson JP, Jones DE, James OF, Cann PA, Bramble MG.Case report: oral antioxidant ther-
apy for the treatment of primary biliary cirrhosis: a pilot study. J Gastroenterol Hepatol.
1999;14(10):1034–40.
82. Walt R, Daneshmend T, Fellows I.Effect of stanozolol on itching in primary biliary cirrhosis.
Br Med J. 1988;296:607.
83. Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis [letter]. Lancet.
1980;2(8193):530.
84. Borgeat A, Wilder-Smith OHG, Mentha G.Subhypnotic doses of propofol relieve pruritus
associated with liver disese. Gastroenterlogy. 1993;104:244–7.
85. Borgeat A, Wilder-Smith O, Saiah M, Rifat K.Subhypnotic doses of propofol relieve pruritus
induced by epidural and intrathecal morphine. Anesthesiology. 1992;76:510–2.
86. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, etal. Preliminary obser-
vation with dronabinol in patients with intractable pruritus secondary to cholestatic liver dis-
ease. Am J Gastroenterol. 2002 Aug;97(8):2117–9.
87. Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efcacy of lidocaine in the
treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med. 2005
Oct;118(10):1160–3.
88. Frezza M, Centini G, Cammareri G, Le Grazie C, Di Padova C. S-adenosylmethionine for
the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial.
Hepatogastroenterology. 1990;37 Suppl 2:122–5.
89. Babatin MA, Sanai FM, Swain MG.Methotrexate therapy for the symptomatic treatment of
primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxy-
cholic acid therapy. Aliment Pharmacol Ther. 2006 Sep 1;24(5):813–20.
90. Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C, Miranda-Romero A.Successful treatment
of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br J Dermatol.
2005 Apr;152(4):808–9.
91. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus
of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006
Nov;44(5):1317–23.
15
Complications ofLiver Disease
https://t.me/medicina_free
478
92. Rishe E, Azarm A, Bergasa NV.Itch in primary biliary cirrhosis: a patients' perspective. Acta
Derm Venereol. 2008;88(1):34–7.
93. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005 Sep
22;353(12):1261–73.
94. Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D.Fatigue in primary biliary cirrhosis
is associated with excessive daytime somnolence. Hepatology. 2006 Jul;44(1):91–8.
95. Jones D, Newton JL.An open study of modanil for the treatment of daytime somnolence
and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;25(4):471–6.
96. Bergasa NV, Mehlman J, Bir K.Aerobic exercise: a potential therapeutic intervention for
patients with liver disease. Med Hypotheses. 2004;62(6):935–41.
97. Schuppan D, Afdhal NH.Liver cirrhosis. Lancet. 2008 Mar 8;371(9615):838–51.
98. Thampanitchawong P, Piratvisuth T.Liver biopsy:complications and risk factors. World J
Gastroenterol. 1999 Aug;5(4):301–4.
99. Bravo AA, Sheth SG, Chopra S.Liver biopsy. N Engl J Med. 2001 Feb 15;344(7):495–500.
100. Berzigotti A, Seijo S, Reverter E, Bosch J.Assessing portal hypertension in liver diseases.
Expert Rev Gastroenterol Hepatol. 2013 Feb;7(2):141–55.
101. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC.Portal hypertension and gastrointesti-
nal bleeding. Semin Liver Dis. 2008 Feb;28(1):3–25.
102. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Fernandez M, Bosch
J, etal. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to
reduced nitric oxide bioavailability. Hepatology. 2008 Apr;47(4):1248–56.
103. Iwakiri Y, Groszmann RJ.Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007
May;46(5):927–34.
104. Bosch J.Vascular deterioration in cirrhosis: the big picture. J Clin Gastroenterol. 2007 Nov-
Dec;41(Suppl 3):S247–53.
105. Bosch J, Iwakiri Y.The portal hypertension syndrome: etiology, classication, relevance, and
animal models. Hepatol Int. 2018 Feb;12(Suppl 1):1–10.
106. Wiest R, Groszmann RJ.The paradox of nitric oxide in cirrhosis and portal hypertension: too
much, not enough. Hepatology. 2002 Feb;35(2):478–91.
107. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J.Portal hypertensive bleeding in cirrhosis:
risk stratication, diagnosis, and management: 2016 practice guidance by the American asso-
ciation for the study of liver diseases. Hepatology. 2017 Jan;65(1):310–35.
108. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice guidelines Committee of the
American Association for the study of liver D, practice parameters Committee of the
American College of G. prevention and management of gastroesophageal varices and vari-
ceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922–38.
109. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W.Prevention and management of gastroesoph-
ageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922–38.
110. North Italian Endoscopic Club for the S, Treatment of Esophageal V.Prediction of the rst
variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospec-
tive multicenter study. N Engl J Med. 1988 Oct 13;319(15):983–9.
111. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an
evidence- based approach. Semin Liver Dis. 1999;19(4):475–505.
112. de Franchis R, Baveno VF.Revising consensus in portal hypertension: report of the Baveno
V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J
Hepatol. 2010 Oct;53(4):762–8.
113. Boregowda U, Umapathy C, Halim N, Desai M, Nanjappa A, Arekapudi S, etal. Update on
the management of gastrointestinal varices. World J Gastrointest Pharmacol Ther. 2019 Jan
21;10(1):1–21.
114. Lee SJ, Kim SU, Kim MD, Kim YH, Kim GM, Park SI, etal. Comparison of treatment
outcomes between balloon-occluded retrograde transvenous obliteration and transjugular
intrahepatic portosystemic shunt for gastric variceal bleeding hemostasis. J Gastroenterol
Hepatol. 2017 Aug;32(8):1487–94.
N. V. Bergasa
https://t.me/medicina_free
479
115. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial
vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in
cirrhosis. Hepatology. 1988 Sep-Oct;8(5):1151–7.
116. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, etal. Compensated cirrhosis:
natural history and prognostic factors. Hepatology. 1987 Jan-Feb;7(1):122–8.
117. Guevara M, Uriz J, Ginès P.Prognosis in patients with cirrhosis and ascites. In: AV GP, Rodés
J, Schrier R, editors. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis
and treatment. MA, USA: Malden: Blackwell; 2005. p.260–70.
118. Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H, etal. Natural history of
patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006
Nov;4(11):1385–94.
119. Biselli M, Dall'Agata M, Gramenzi A, Gitto S, Liberati C, Brodosi L, etal. A new prognostic
model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation
with MELD score <18. Liver Int. 2015 Jan;35(1):184–91.
120. Witte MH, Dumont AE, Cole WR, Witte CL, Kintner K.Lymph circulation in hepatic cir-
rhosis: effect of portacaval shunt. Ann Intern Med. 1969 Feb;70(2):303–10.
121. Witte CL, Witte MH, Dumont AE, Frist J, Cole WR.Lymph protein in hepatic cirrhosis and
experimental hepatic and portal venous hypertension. Ann Surg. 1968 Oct;168(4):567–77.
122. Laine GA, Hall JT, Laine SH, Granger J.Transsinusoidal uid dynamics in canine liver dur-
ing venous hypertension. Circ Res. 1979 Sep;45(3):317–23.
123. Witte MH, Witte CL, Dumont AE.Progress in liver disease: physiological factors involved in
the causation of cirrhotic ascites. Gastroenterology. 1971 Nov;61(5):742–50.
124. Brauer RW, Holloway RJ, Leong GF.Changes in liver function and structure due to experi-
mental passive congestion under controlled hepatic vein pressures. Am J Phys. 1959
Sep;197:681–92.
125. Granger DN, Miller T, Allen R, Parker RE, Parker JC, Taylor AE.Permselectivity of cat blood-
lymph barrier to endogenous macromolecules. Gastroenterology. 1979 Jul;77(1):103–9.
126. Granger HJ, Laine GA.Consecutive barriers to movement of water and solutes across the
liver sinusoids. Physiologist. 1980 Feb;23(1):83–5.
127. Witte CL, Witte MH, Cole WR, Chung YC, Bleisch VR, Dumont AE.Dual origin of ascites
in hepatic cirrhosis. Surg Gynecol Obstet. 1969 Nov;129(5):1027–33.
128. Witte MH, Witte CL, Dumont AE. Estimated net transcapillary water and protein ux
in the liver and intestine of patients with portal hypertension from hepatic cirrhosis.
Gastroenterology. 1981 Feb;80(2):265–72.
129. Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. Gastroenterology. 1963
Mar;44:239–42.
130. Dumont AE, Witte CL, Witte MH.Protein content of liver lymph in patients with portal
hypertension secondary to hepatic cirrhosis. Lymphology. 1975 Dec;8(4):111–3.
131. Huet PM, Goresky CA, Villeneuve JP, Marleau D, Lough JO.Assessment of liver microcir-
culation in human cirrhosis. J Clin Invest. 1982 Dec;70(6):1234–44.
132. Fernandez-Llama P, Gines P, Schrier RW.Pathogenesis of sodium retention in cirrhosis: the
arterial vasodilation hypothesis of ascites formation. In: Ginès P, Rodés J, Schrier R, editors.
Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis and treatment. MA,
USA: Malden: Blackwell; 2005. p.201–13.
133. Caregaro L, Lauro S, Angeli P, Merkel C, Gatta A.Renal water and sodium handling in
compensated liver cirrhosis: mechanism of the impaired natriuresis after saline loading. Eur
J Clin Investig. 1985 Dec;15(6):360–4.
134. Wood LJ, Massie D, McLean AJ, Dudley FJ.Renal sodium retention in cirrhosis: tubular site
and relation to hepatic dysfunction. Hepatology. 1988 Jul-Aug;8(4):831–6.
135. Denison EK, Lieberman FL, Reynolds TB. 9- -uorohydrocortisone induced ascites in alco-
holic liver disease. Gastroenterology. 1971 Oct;61(4):497–503.
136. Wilkinson SP, Jowett TP, Slater JD, Arroyo V, Moodie H, Williams R.Renal sodium retention
in cirrhosis: relation to aldosterone and nephron site. Clin Sci. 1979 Feb;56(2):169–77.
15
Complications ofLiver Disease
https://t.me/medicina_free
480
137. Arroyo V, Rodes J, Gutierrez-Lizarraga MA, Revert L. Prognostic value of spontaneous
hyponatremia in cirrhosis with ascites. Am J Dig Dis. 1976 Mar;21(3):249–56.
138. Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, etal. Hyponatremia in cir-
rhosis: from pathogenesis to treatment. Hepatology. 1998 Sep;28(3):851–64.
139. Hoefs JC.Serum protein concentration and portal pressure determine the ascitic uid protein
concentration in patients with chronic liver disease. J Lab Clin Med. 1983 Aug;102(2):260–73.
140. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG.The
serum-ascites albumin gradient is superior to the exudate-transudate concept in the differen-
tial diagnosis of ascites. Ann Intern Med. 1992 Aug 1;117(3):215–20.
141. Thomsen TW, Shaffer RW, White B, Setnik GS.Videos in clinical medicine. Paracentesis. N
Engl J Med. 2006 Nov 9;355(19):e21.
142. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, etal. The management of
ascites in cirrhosis: report on the consensus conference of the international Ascites Club.
Hepatology. 2003 Jul;38(1):258–66.
143. Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, etal. Peritoneovenous
shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive
ascites. Veterans administration cooperative study on treatment of alcoholic cirrhosis with
Ascites. N Engl J Med. 1989 Dec 14;321(24):1632–8.
144. Runyon BA. Introduction to the revised American Association for the Study of Liver
Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012.
Hepatology. 2013 Apr;57(4):1651–3.
145. European Association for the Study of the Liver. Electronic address eee, European Association
for the Study of the L.EASL clinical practice guidelines for the management of patients with
decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406–60.
146. Pockros PJ, Reynolds TB.Rapid diuresis in patients with ascites from chronic liver disease:
the importance of peripheral edema. Gastroenterology. 1986 Jun;90(6):1827–33.
147. El-Bokl MA, Senousy BE, El-Karmouty KZ, Mohammed Iel K, Mohammed SM, Shabana
SS, etal. Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites.
World J Gastroenterol. 2009 Aug 7;15(29):3631–5.
148. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laf G, etal. Denition and diagnostic
criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Int Ascites Club Hepatol.
1996 Jan;23(1):164–76.
149. Salerno F, Badalamenti S, Incerti P, Tempini S, Restelli B, Bruno S, etal. Repeated paracen-
tesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative
therapy. J Hepatol. 1987 Aug;5(1):102–8.
150. Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, etal. Comparison of paracentesis
and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.
Gastroenterology. 1987 Aug;93(2):234–41.
151. Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, etal. Comparison
of outcome in patients with cirrhosis and ascites following treatment with albumin or a syn-
thetic colloid: a randomised controlled pilot trail. Liver Int. 2006 Feb;26(1):46–54.
152. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, etal. Diuretic
requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A ran-
domized double-blind trial of spironolactone versus placebo. J Hepatol. 1997 Mar;26(3):
614–20.
153. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, etal. A comparison of para-
centesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl
J Med. 2000 Jun 8;342(23):1701–7.
154. Dariushnia SR, Haskal ZJ, Midia M, Saiter CK, Nikolic B.Quality improvement guidelines
for Transjugular intrahepatic portosystemic. J Vasc Interv Radiol. 2016;27(1):1–7.
155. Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta
PK.Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized
pilot study. J Hepatol. 2012;56:348–54.
N. V. Bergasa
https://t.me/medicina_free
481
156. Wong F, Bendel E, Sniderman K, Frederick T, Haskal ZJ, Sanyal A, et al. Improvement in
quality of life and decrease in large volume paracentesis requirements with the automated
low ow Ascites pump. Liver Transpl. 2020 Jan 30;
157. Garbuzenko DV, Arefyev NO.Hepatic hydrothorax: an update and review of the literature.
World J Hepatol. 2017 Nov 8;9(31):1197–204.
158. Huang PM, Kuo SW, Chen JS, Lee JM.Thoracoscopic mesh repair of diaphragmatic defects
in hepatic hydrothorax: a 10-year experience. Ann Thorac Surg. 2016 May;101(5):1921–7.
159. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, et al.
Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol.
2005 Feb;42(2):195–201.
160. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005
Mar;41(3):422–33.
161. Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, etal. Neutrophil
dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the
outcome. Hepatology. 2007 Sep;46(3):831–40.
162. Such J, Runyon BA.Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27(4):669–74.
quiz 75-6
163. Bellot P, Frances R, Such J.Pathological bacterial translocation in cirrhosis: pathophysiol-
ogy, diagnosis and clinical implications. Liver Int. 2013 Jan;33(1):31–9.
164. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, etal. Duration of hypoten-
sion before initiation of effective antimicrobial therapy is the critical determinant of survival
in human septic shock. Crit Care Med. 2006 Jun;34(6):1589–96.
165. Garcia-Tsao G. Spontaneous bacterial peritonitis. Gastroenterol Clin N Am. 1992
Mar;21(1):257–75.
166. Mandorfer M, Bota S, Schwabl P, Bucsics T, Psterer N, Kruzik M, etal. Nonselective beta
blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and
spontaneous bacterial peritonitis. Gastroenterology. 2014 Jun;146(7):1680–90 e1.
167. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, etal. Diagnosis and manage-
ment of acute kidney injury in patients with cirrhosis: revised consensus recommendations of
the International Club of Ascites. Gut. 2015 Apr;64(4):531–7.
168. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, etal. Evaluation of the acute
kidney injury network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol.
2013 Sep;59(3):482–9.
169. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, etal. Association of
AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology.
2013 Feb;57(2):753–62.
170. Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, etal. Management
of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol. 2016
Mar;64(3):717–35.
171. Umgelter A, Reindl W, Wagner KS, Franzen M, Stock K, Schmid RM, etal. Effects of plasma
expansion with albumin and paracentesis on haemodynamics and kidney function in criti-
cally ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncon-
trolled trial. Crit Care. 2008;12(1):R4.
172. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V.Diagnosis, prevention and treatment of
hepatorenal syndrome in cirrhosis. Gut. 2007 Sep;56(9):1310–8.
173. Puthumana J, Ariza X, Belcher JM, Graupera I, Gines P, Parikh CR.Urine interleukin 18 and
Lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: a systematic
review and meta-analysis. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1003–13 e3.
174. Schrier R, Arroyo V, Bernardi M, Epstein M, Henriksen J, Rodés J.Peripheral arterial vasodi-
lation hypothesis: a proposal for the initiationof renal sodium andwater retention in cirrhosis.
Hepatology. 1988;8:1151–7.
175. Ring-Larsen H.Renal blood ow in cirrhosis: relation to systemic and portal haemodynamics
and liver function. Scand J Clin Lab Invest. 1977 Nov;37(7):635–42.
15
Complications ofLiver Disease
https://t.me/medicina_free
482
176. Cohn JN. Renal hemodynamic alterations in liver disease. Perspect Nephrol Hypertens.
1976;3:255–34.
177. Iwakiri Y, Groszmann RJ.The hyperdynamic circulation of chronic liver diseases: from the
patient to the molecule. Hepatology. 2006 Feb;43(2 Suppl 1):S121–31.
178. Wong F, Leung W, Al Beshir M, Marquez M, Renner EL.Outcomes of patients with cirrho-
sis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl. 2015
Mar;21(3):300–7.
179. Szeto HH, Liu S, Soong Y, Seshan SV, Cohen-Gould L, Manichev V, et al. Mitochondria
protection after acute ischemia prevents prolonged upregulation of IL-1beta and IL-18 and
arrests CKD.J Am Soc Nephrol. 2017 May;28(5):1437–49.
180. van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common
pathologic nding for kidney injury associated with severe liver dysfunction. Kidney Int.
2013 Jul;84(1):192–7.
181. Chatrath H, Liangpunsakul S, Ghabril M, Otte J, Chalasani N, Vuppalanchi R. Prevalence
and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med. 2012
Oct;125(10):1019–25.
182. Angeli P, Albino G, Carraro P, Dalla Pria M, Merkel C, Caregaro L, et al. Cirrhosis and
muscle cramps: evidence of a causal relationship. Hepatology. 1996 Feb;23(2):264–73.
183. Elfert AA, Abo Ali L, Soliman S, Zakaria S, Shehab El-Din I, Elkhalawany W, et al.
Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in
patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1280–4.
184. Butterworth RF, Giguere JF, Michaud J, Lavoie J, Layrargues GP.Ammonia: key factor in the
pathogenesis of hepatic encephalopathy. Neurochem Pathol. 1987 Feb-Apr;6(1–2):1–12.
185. Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver
Dis. 1996 Aug;16(3):245–53.
186. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encepha-
lopathy in chronic liver disease: 2014 practice guideline by the American Association for the
Study of Liver Diseases and the European Association for the Study of the liver. Hepatology.
2014 Aug;60(2):715–35.
187. Jayakumar AR, Norenberg MD. Hyperammonemia in hepatic encephalopathy. J Clin Exp
Hepatol. 2018 Sep;8(3):272–80.
188. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, etal. Prognostic signi-
cance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999 May;30(5):890–5.
189. Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, etal. High prevalence
of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control
study. Hepatology. 2005 Nov;42(5):1158–65.
190. Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric-acid neu-
rotransmitter system. Lancet. 1982 Jan 2;1(8262):18–20.
191. Basile AS, Jones EA, Skolnick P.The pathogenesis and treatment of hepatic encephalopa-
thy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev. 1991
Mar;43(1):27–71.
192. Basile AS, Harrison PM, Hughes RD, Gu ZQ, Pannell L, McKinney A, et al. Relationship
between plasma benzodiazepine receptor ligand concentrations and severity of hepatic
encephalopathy. Hepatology. 1994 Jan;19(1):112–21.
193. Basile AS, Jones EA.Ammonia and GABA-ergic neurotransmission: interrelated factors in
the pathogenesis of hepatic encephalopathy. Hepatology. 1997 Jun;25(6):1303–5.
194. Norenberg MD.Astroglial dysfunction in hepatic encephalopathy. Metab Brain Dis. 1998
Dec;13(4):319–35.
195. Bender AS, Norenberg MD. Effect of benzodiazepines and neurosteroids on ammonia-
induced swelling in cultured astrocytes. J Neurosci Res. 1998 Dec 1;54(5):673–80.
196. Butterworth RF.Neurosteroids in hepatic encephalopathy: novel insights and new therapeutic
opportunities. J Steroid Biochem Mol Biol. 2016 Jun;160:94–7.
197. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol. 1997
Sep;92(9):1429–39.
198. Mohiuddin SSKD.Biochemistry, ammonia. Treasure Island: Florida; 2019.
N. V. Bergasa
https://t.me/medicina_free
483
199. Walker V. Ammonia metabolism and hyperammonemic disorders. Adv Clin Chem.
2014;67:73–150.
200. Als-Nielsen B, Gluud LL, Gluud C.Benzodiazepine receptor antagonists for hepatic enceph-
alopathy. Cochrane Database Syst Rev. 2004;2:CD002798.
201. Wijdicks EF.Hepatic encephalopathy. N Engl J Med. 2016 Oct 27;375(17):1660–70.
202. Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, etal. Impaired
gut-liver-brain Axis in patients with cirrhosis. Sci Rep. 2016 May 26;6:26800.
203. Romero-Gomez M, Jover M, Del Campo JA, Royo JL, Hoyas E, Galan JJ, etal. Variations in
the promoter region of the glutaminase gene and the development of hepatic encephalopathy
in patients with cirrhosis: a cohort study. Ann Intern Med. 2010 Sep 7;153(5):281–8.
204. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT.Hepatic encepha-
lopathy--denition, nomenclature, diagnosis, and quantication: nal report of the work-
ing party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology. 2002
Mar;35(3):716–21.
205. Weissenborn K, Ruckert N, Hecker H, Manns MP.The number connection tests a and B:
interindividual variability and use for the assessment of early hepatic encephalopathy. J
Hepatol. 1998 Apr;28(4):646–53.
206. Parsons-Smith BG, Summerskill WH, Dawson AM, Sherlock S.The electroencephalograph
in liver disease. Lancet. 1957 Nov 2;273(7001):867–71.
207. Amodio P, Montagnese S.Clinical neurophysiology of hepatic encephalopathy. J Clin Exp
Hepatol. 2015 Mar;5(Suppl 1):S60–8.
208. Han KH.Mechanisms of the effects of acidosis and hypokalemia on renal ammonia metabo-
lism. Electrolyte & Blood Pressure: E & BP. 2011 Dec;9(2):45–9.
209. Shehata HH, Elfert AA, Abdin AA, Soliman SM, Elkhouly RA, Hawash NI, etal. Randomized
controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic
encephalopathy. Eur J Gastroenterol Hepatol. 2018 Dec;30(12):1476–81.
210. Ferenci P. Treatment options for hepatic encephalopathy: a review. Serminars Liver Dis.
2007;27(S2):10–7.
211. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L, etal. Acidifying enemas (lac-
titol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encepha-
lopathy: a double-blind, randomized clinical trial. Hepatology. 1987 Jul-Aug;7(4):639–43.
212. Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, etal. Effect of lactitol
and lactulose administration on the fecal ora in cirrhotic patients. J Clin Gastroenterol. 1990
Aug;12(4):433–6.
213. Portalatin M, Winstead N.Medical management of constipation. Clin Colon Rectal Surg.
2012 Mar;25(1):12–9.
214. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol
3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP random-
ized clinical trial. JAMA Intern Med. 2014 Nov;174(11):1727–33.
215. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, etal. Rifaximin treatment in
hepatic encephalopathy. N Engl J Med. 2010 Mar 25;362(12):1071–81.
216. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.A randomized, double-
blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of
overt hepatic encephalopathy. Am J Gastroenterol. 2013 Sep;108(9):1458–63.
217. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, etal. Cirrhotic
cardiomyopathy. J Am Coll Cardiol. 2010 Aug 10;56(7):539–49.
218. Wiese S, Hove JD, Bendtsen F, Moller S.Cirrhotic cardiomyopathy: pathogenesis and clini-
cal relevance. Nat Rev Gastroenterol Hepatol. 2014 Mar;11(3):177–86.
219. Chen Y, Chan AC, Chan SC, Chok SH, Sharr W, Fung J, etal. A detailed evaluation of cardiac
function in cirrhotic patients and its alteration with or without liver transplantation. J Cardiol.
2016 Feb;67(2):140–6.
220. Moller S, Hove JD, Dixen U, Bendtsen F.New insights into cirrhotic cardiomyopathy. Int J
Cardiol. 2013 Aug 20;167(4):1101–8.
221. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB, Committee ERSTFP-
HVDS.Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004 Nov;24(5):861–80.
15
Complications ofLiver Disease
https://t.me/medicina_free
484
222. Cremona G, Higenbottam TW, Mayoral V, Alexander G, Demoncheaux E, Borland C, etal.
Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J. 1995
Nov;8(11):1883–5.
223. Zhang M, Luo B, Chen SJ, Abrams GA, Fallon MB.Endothelin-1 stimulation of endothelial
nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Phys. 1999
Nov;277(5):G944–52.
224. Katsuta Y, Zhang XJ, Ohsuga M, Akimoto T, Komeichi H, Shimizu S, etal. Arterial hypox-
emia and intrapulmonary vasodilatation in rat models of portal hypertension. J Gastroenterol.
2005 Aug;40(8):811–9.
225. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, etal. Role of nitric oxide
in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001 Sep
1;164(5):879–85.
226. Zhang HY, Han DW, Wang XG, Zhao YC, Zhou X, Zhao HZ.Experimental study on the role
of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol. 2005
Jan 28;11(4):567–72.
227. Arguedas MR, Drake BB, Kapoor A, Fallon MB. Carboxyhemoglobin levels in cir-
rhotic patients with and without hepatopulmonary syndrome. Gastroenterology. 2005
Feb;128(2):328–33.
228. Liu L, Liu N, Zhao Z, Liu J, Feng Y, Jiang H, etal. TNF-alpha neutralization improves experi-
mental hepatopulmonary syndrome in rats. Liver Int. 2012 Jul;32(6):1018–26.
229. Rodriguez-Roisin R, Roca J, Agusti AG, Mastai R, Wagner PD, Bosch J. Gas exchange
and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis. 1987
May;135(5):1085–92.
230. Berthelot P, Walker JG, Sherlock S, Reid L.Arterial changes in the lungs in cirrhosis of the
liver--lung spider nevi. N Engl J Med. 1966 Feb 10;274(6):291–8.
231. Abrams GA, Sanders MK, Fallon MB.Utility of pulse oximetry in the detection of arterial
hypoxemia in liver transplant candidates. Liver Transpl. 2002 Apr;8(4):391–6.
232. Arguedas MR, Singh H, Faulk DK, Fallon MB.Utility of pulse oximetry screening for hepa-
topulmonary syndrome. Clin Gastroenterol Hepatol. 2007 Jun;5(6):749–54.
233. Wolfe JD, Tashkin DP, Holly FE, Brachman MB, Genovesi MG.Hypoxemia of cirrhosis:
detection of abnormal small pulmonary vascular channels by a quantitative radionuclide
method. Am J Med. 1977 Nov;63(5):746–54.
234. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB.Use of macroaggregated
albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach.
Gastroenterology. 1998 Feb;114(2):305–10.
235. Eriksson LS, Soderman C, Ericzon BG, Eleborg L, Wahren J, Hedenstierna G.Normalization
of ventilation/perfusion relationships after liver transplantation in patients with decompen-
sated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology. 1990 Dec;12(6):
1350–7.
236. Gupta S, Castel H, Rao RV, Picard M, Lilly L, Faughnan ME, etal. Improved survival after
liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant. 2010
Feb;10(2):354–63.
237. Chevallier P, Novelli L, Motamedi JP, Hastier P, Brunner P, Bruneton JN.Hepatopulmonary
syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-
year follow-up. J Vascular Int Radiol: JVIR. 2004 Jun;15(6):647–8.
238. Tsauo J, Weng N, Ma H, Jiang M, Zhao H, Li X. Role of Transjugular intrahepatic porto-
systemic shunts in the Management of Hepatopulmonary Syndrome: a systemic literature
review. J Vascular Int Radiol: JVIR. 2015 Sep;26(9):1266–71.
239. Grady K, Gowda S, Kingah P, Soubani AO. Coil embolization of pulmonary arteries
as a palliative treatment of diffuse type I hepatopulmonary syndrome. Respir Care. 2015
Feb;60(2):e20–5.
240. De BK, Dutta D, Pal SK, Gangopadhyay S, Das Baksi S, Pani A. The role of garlic in
hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol. 2010
Mar;24(3):183–8.
N. V. Bergasa
https://t.me/medicina_free
485
241. Savale L, Watherald J, Sitbon O.Portopulmonary hypertension. Semin Respir Crit Care Med.
2017 Oct;38(5):651–61.
242. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, etal. Genetic risk factors
for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit
Care Med. 2009 May 1;179(9):835–42.
243. Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, etal. Portopulmonary hyper-
tension in the current era of pulmonary hypertension management. J Hepatol. 2020 Mar;4
244. Pilatis ND, Jacobs LE, Rerkpattanapipat P, Kotler MN, Owen A, Manzarbeitia C, etal.
Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evalua-
tion. Liver Transpl. 2000 Jan;6(1):85–91.
245. Krowka MJ, Edwards WD.A spectrum of pulmonary vascular pathology in portopulmonary
hypertension. Liver Transpl. 2000 Mar;6(2):241–2.
246. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, etal. Pathologic assess-
ment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12
Suppl S):25S–32S.
247. Giaid A, Saleh D.Reduced expression of endothelial nitric oxide synthase in the lungs of
patients with pulmonary hypertension. N Engl J Med. 1995 Jul 27;333(4):214–21.
248. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, etal. Big endo-
thelin- 1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary
hypertension. Chest. 2001 Nov;120(5):1562–9.
249. Maruyama T, Ohsaki K, Shimoda S, Kaji Y, Harada M.Thromboxane-dependent portopul-
monary hypertension. Am J Med. 2005 Jan;118(1):93–4.
250. Pellicelli AM, Barbaro G, Puoti C, Guarascio P, Lusi EA, Bellis L, etal. Plasma cytokines
and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver trans-
plantation. Angiology. 2010 Nov;61(8):802–6.
251. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, etal. Diagnosis of
portopulmonary hypertension in candidates for liver transplantation: a prospective study.
Hepatology. 2003 Feb;37(2):401–9.
252. Krowka MJ. Treatment of Portopulmonary hypertension with Macitentan in patients with
cirrhosis. Gastroenterol Hepatol. 2019;15(2):108–10.
253. Stibon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin
N, Savale L, Krowka M. Macitentan for the treatment of portopulmonary hypertension
(PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Lancet. 2019;7(7):594–604.
254. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O.Deleterious
effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmo-
nary hypertension. Gastroenterology. 2006;130(1):120–6.
255. G-P RE, Reixach M, Cuso E, Rodes J. Fat digestion and exocrine pancreatic function in
primary biliary cirrhosis. Gastroenteorlogy. 1984;1984(1):180–7.
256. Logan RF, Ferguson A, Finlayson ND, Weir DG.Primary biliary cirrhosis and coeliac dis-
ease: an association? Lancet. 1978;1(8058):230–3.
257. Fidler HM, Butler P, Burroughs AK, McIntyre N, Bunn C, McMorrow M, Walmsley R,
Dooley J.Co-screening for primary biliary cirrhosis and coeliac disease: a study of relative
prevalences. Gut. 1998;43(2):300.
258. Kanai M, Raz A, Goodman DS.Retinol-binding protein: the transport protein for vitamin a
in human plasma. J Clin Invest. 1968;47(9):2025–44.
259. Russell RM. The vitamin a spectrum: from deciency to toxicity. Am J Clin Nutr. 2000
Apr;71(4):878–84.
260. Walt RP, Kemp CM, Lyness L, Bird AC, Sherlock S.Vitamin a treatment for night blindness
in primary biliary cirrhosis. Br Med J. 1984;288(6423):1020–31.
261. Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin
Liver Dis. 1999 Aug;3(3):529–70.
262. Danielsson A, Lorentzon R, Larsson SE.Intestinal absorption and 25-hydroxylation of vita-
min D in patients with primary biliary cirrhosis. Scand J Gastroenterol. 1982;17:349–55.
15
Complications ofLiver Disease
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана